Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme

Switch Atlas

Source

Dermatology Times: FDA Approves RP1 (Vusolimogene Oderparepvec) Plus Nivolumab for Advanced Melanoma

Web Source
Facts
URL
https://www.dermatologytimes.com/view/fda-approves-rp1-plus-nivolumab-for-advanced-melanoma
Sources
Dermatology Times: FDA Approves RP1 (Vusolimogene Oderparepvec) Plus Nivolumab for Advanced Melanoma
View the Source
Claims Backed By This Source (3 claims)

This source backs 3 claims across the atlas. As facts: 2 well-attested. Plus 1 entities citing it as a general reference with no single fact or relationship attached.

Disposition By Topic

  • Drugs and Medicinal Substances, 2 claims: 1 well-attested, 1 general references.
  • Sources, 1 claims: 1 well-attested.

Well-attested

2

Drugs and Medicinal Substances

Vusolimogene oderparepvec

Sources

Dermatology Times: FDA Approves RP1 (Vusolimogene Oderparepvec) Plus Nivolumab for Advanced Melanoma

General References

1

Drugs and Medicinal Substances

Vusolimogene oderparepvec
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.